Last reviewed · How we verify
Therion Biologics Corporation — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| PANVAC™-VF | PANVAC™-VF | phase 3 | Therapeutic cancer vaccine | ras and CEA (carcinoembryonic antigen) | Oncology |
Therapeutic area mix
- Oncology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- CancerVax Corporation · 1 shared drug class
- Centre Leon Berard · 1 shared drug class
- Chiang Mai University · 1 shared drug class
- Chiltern Pesquisa Clinica Ltda · 1 shared drug class
- GERCOR - Multidisciplinary Oncology Cooperative Group · 1 shared drug class
- Galena Biopharma, Inc. · 1 shared drug class
- Genocea Biosciences, Inc. · 1 shared drug class
- GlaxoSmithKline · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Therion Biologics Corporation:
- Therion Biologics Corporation pipeline updates — RSS
- Therion Biologics Corporation pipeline updates — Atom
- Therion Biologics Corporation pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Therion Biologics Corporation — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/therion-biologics-corporation. Accessed 2026-05-17.